NCT05186194 is a NA clinical trial of Vitamin D, Calcium in Stress Fracture, sponsored by Xijing Hospital.

Who is sponsoring NCT05186194?

NCT05186194 is sponsored by Xijing Hospital.

What drugs are being tested in NCT05186194?

Interventions in NCT05186194: Vitamin D, Calcium, Placebo.

What condition does NCT05186194 study?

NCT05186194 studies Stress Fracture, Vitamin d.

Is NCT05186194 still recruiting?

NCT05186194 is currently status unknown. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT05186194

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Vitamin D and Calcium Supplementation on the Prevention of Stress Fractures.

Status unknown NA Last updated 11 January 2022

What this trial tests

NA trial testing Vitamin D, Calcium in Stress Fracture in 240 participants. Status unknown.

Timeline

30 September 2021

Primary endpoint
30 June 2022

30 September 2022

Quick facts

Lead sponsor	Xijing Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	240
Start date	30 September 2021
Primary completion	30 June 2022
Estimated completion	30 September 2022
Sites	1 location across China

Drugs / interventions tested

Vitamin D, Calcium — full drug profile →
Placebo

Conditions studied

Stress Fracture — all drugs for Stress Fracture →
Vitamin d — all drugs for Vitamin d →

Sponsor

Xijing Hospital

Who can join

Adults 18 to 25, any sex, with Stress Fracture or Vitamin d. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective of this study is to find whether supplemental vitamin d and calcium can reduce the incidence of stress fractures in recruits. These high-risk recruits undergo intensive training which elevated bone turnover, which requires adequate level of vitamin D and calcium in order to support bone health. It is hypothesized that supplemental vitamin d and calcium will decrease the occurrence of stress fractures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Xijing Hospital trials

Trials by the same sponsor.

NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05186194 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05186194.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing